多奈哌齐联合参志胶囊治疗帕金森病患者的效果及对血清CysC、Hcy和脑神经递质水平的影响

Effect of donepezil combined with Shenzhi capsule on patients with Parkinson’s disease and its influence on serum Cys C,Hcy and brain neurotransmitter levels

目的观察多奈哌齐联合参志胶囊治疗帕金森病患者的效果及对血清血清胱抑素C(Cys C)、同型半胱氨酸(Hcy)和脑神经递质水平的影响。方法选取2017年9月-2019年8月广西壮族自治区民族医院神经内科收治的帕金森病患者90例为研究对象,根据随机数字表法分为观察组和对照组,每组45例。对照组口服多奈哌齐治疗,观察组在对照组基础上口服参志胶囊治疗。比较2组临床疗效,治疗前后血清Cys C、Hcy和脑神经递质水平,以及不良反应发生率。结果治疗3个月,观察组总有效率为95.56%,高于对照组的77.78%(χ^(2)=4.712,P=0.030);治疗3个月后,2组血清Cys C、Hcy水平较治疗前均有所下降,且观察组下降幅度大于对照组(P均<0.01);治疗3个月后,2组乙酰胆碱(ACh)、5-羟色胺(5-HT)水平与治疗前及组间比较差异均无统计学意义(P>0.05),但2组多巴胺(DA)水平均较治疗前升高,且观察组DA水平高于对照组(P<0.01);观察组治疗期间不良反应总发生率为4.44%,低于对照组的24.44%(χ^(2)=5.754,P=0.016)。结论多奈哌齐联合参志胶囊可明显提高帕金森患者的临床疗效,同时降低血清Cys C、Hcy水平,提高DA水平,且不良反应少,值得神经内科推广应用。

Objective To observe the therapeutic effect of donepezil combined with Shenzhi capsule on patients with Parkinson’s disease and the influence on serum Cys C,Hcy and brain neurotransmitter levels. Methods 90 patients with Parkinson’s disease who were admitted to the department of Neurology of National Hospital of Guangxi Zhuang Autonomous Region from September 2017 to August 2019 were selected as the research objects. According to the random number table method,they were divided into observation group and control group,with 45 cases in each group. The control group was treated with donepezil orally,and the observation group was treated with Shenzhi capsule orally on the basis of the control group. The clinical efficacy of the two groups were compared,the levels of serum Cys C,Hcy and brain neurotransmitters before and after treatment,and the incidence of adverse reactions in the two groups. Results After 3 months of treatment,the total effective rate in the observation group was 95. 56%,which was higher than 77. 78% in the control group( χ^(2)= 4. 712,P = 0. 030). After3 months of treatment,the levels of serum Cys C and Hcy in the two groups decreased compared with those before treatment,and the decrease in the observation group was greater than that in the control group( P < 0. 01). There was no significant difference in the levels of acetylcholine( ACh) and 5-hydroxytryptamine( 5-HT) between the two groups before and after treatment( P > 0. 05),but the levels of dopamine( DA) in the two groups were higher than before treatment,and the DA levels in the observation group were higher than those in the control group( P < 0. 01). The total incidence of adverse reactions during treatment in the observation group was 4. 44%,which was lower than 24. 44% in the control group( χ^(2)= 5. 754,P = 0. 016).Conclusion Donepezil combined with Shenzhi capsule can significantly improve the clinical efficacy of Parkinson’ s disease patients,with less adverse reactions. At the same time,it can reduce the serum Cys C and Hcy levels,and improve the level of dopamine,which is worthy of promotion and use in neurology.